Collectively, our results delineated that LAPTM5 ameliorates the development of pathological cardiac hypertrophy by interacting with Rac1 and then blocking the activation of the Rac1-dependent signaling cascade. This evidence concerns the gene RAC1 and cardiac hypertrophy.